VMI
SIOX

VHCP Management II’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

VHCP Management II’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-9,520
Closed -$524K – 22
2017
Q3 		$524K Sell
9,520
-28,195
-75% -$4.76M 0.14% 21
2017
Q2 		$7M Sell
37,715
-15,984
-30% -$2.8M 2.79% 9
2017
Q1 		$6.42M Hold
53,699
– – 2.63% 8
2016
Q4 		$5.34M Hold
53,699
– – 2.56% 10
2016
Q3 		$6.01M Hold
53,699
– – 3.09% 10
2016
Q2 		$5.52M Hold
53,699
– – 3.33% 10
2016
Q1 		$4.93M Buy
+53,699
New +$5.73M 3.24% 11

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VHCP Management II's SIOX Position: Q4 2017 in Review

VHCP Management II sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 9,520 shares — an estimated $524K sold.

VHCP Management II first reported a position in SIOX in Q1 2016 and held it in 7 quarters. The position peaked at $7M in Q2 2017. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • VHCP Management II reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • VHCP Management II sold 9,520 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $524K.
  • VHCP Management II first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2016 and held it in 7 quarters.
  • VHCP Management II's Sio Gene Therapies Inc. Common Stock position peaked at $7M in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on VHCP Management II's 13F filing for Q4 2017, filed 13 Feb 2018.